In a statement, CRN President and CEO Steve Mister said he was “alarmed” at the FDA’s decision and that the CRN was “evaluating its options in response”.

“Prior to the release of its October 11 and November 4 letters, the agency had acknowledged a New Dietary Ingredient Notification for β-NMN without objection,” he said. “Additionally, FDA has not previously raised any concerns publicly about the ingredient being used in dietary supplements.”

“Much of the innovation for dietary supplements comes from the introduction of new ingredients. But FDA’s actions demonstrate a disregard for consumers who benefit from the innovation and investments of dietary supplement companies.”

This is the company acquiring the "rights" to this compound essentially, using the FDA, an unelected bureaucracy to manipulate markets without prosecution.